Table 1

Baseline characteristics and treatment details of the safety population

Patient characteristicRivaroxabanLWMH/VKA n = 137
20 mg, n = 13530 mg, n = 13440 mg, n = 136
Male sex, n (%)64 (47)69 (51)71 (52)73 (53)
Age, y (range)*58 (22-87)57 (18-89)60 (22-94)57 (21-92)
Weight, kg (range)80 (45-140)81 (40-140)81 (37-154)79 (41-134)
BMI, kg/m2 (range)28 (16-47)27 (18-53)28 (15-45)27 (18-39)
Active cancer, n (%)11 (8)14 (10)16 (12)10 (7)
Previous DVT or PE, n (%)28 (21)25 (19)31 (23)40 (29)
Recent surgery or trauma, n (%)26 (19)36 (27)30 (22)33 (24)
Recent immobilization for >3 days, n (%)18 (13)20 (15)21 (15)18 (13)
Most proximal DVT location, n (%)
    Trifurcation8 (6)6 (4)6 (4)4 (3)
    Popliteal vein48 (37)46 (35)44 (33)49 (37)
    Superficial femoral vein31 (24)38 (29)38 (29)32 (24)
    Common femoral vein44 (34)42 (32)45 (34)49 (37)
Perfusion defect at baseline, n (%)90 (67)103 (77)91 (67)89 (65)
Rivaroxaban trough levels at day 43, median (IQR) ng/mL32 (19-60)47 (24-83)50 (31-96)
Rivaroxaban peak levels at day 84, median (IQR) ng/mL244 (175-360)293 (184-399)365 (205-564)
Premature discontinuation, n (%)17 (13)19 (14)12 (9)15 (11)
    Adverse event, n (%)9 (7)7 (5)5 (4)5 (4)
    Consent withdrawn, n (%)2 (1)2 (1)2 (1)3 (2)
    Other, n (%)6 (4)10 (7)5 (4)7 (5)
  • BMI indicates body mass index; IQR, interquartile range; and —, not applicable.